Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518

Kairos Pharma, LTD.

KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.
Preclinical study showed KROS101 enhanced T cell cytotoxicity and cytokine production, boosting tumor cell killing.
KROS101 was superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg reduction, and preventing T cell exhaustion.
CEO Dr. John Yu presented findings at ASCO 2025 (May 30-June 3) and expressed strong support for continued study of KROS101.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.